The asthma and COPD drugs market size has grown strongly in recent years. It will grow from $32.52 billion in 2024 to $35.66 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. This growth during the historical period is primarily attributed to increasing levels of air pollution, a rise in smoking habits, heightened awareness of respiratory illnesses, growing usage of corticosteroids and bronchodilators, and an increase in healthcare spending.
The asthma and COPD drugs market size is expected to see strong growth in the next few years. It will grow to $50.99 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. This anticipated growth is driven by the rising preference for personalized treatment approaches, the growing use of biologics and next-generation therapies, a surge in environmental allergy cases, expansion in clinical trials and regulatory approvals, and the increasing prevalence of chronic non-communicable diseases. Notable trends projected during the forecast period include the emergence of smart inhaler technologies, development of dual-action bronchodilators, integration of drug data with electronic health records (EHRs), advancements in biopharmaceutical innovations, and the application of machine learning in the drug development process.
Major players in the asthma and COPD drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd. (Roche), Merck & Co. Inc., Sanofi, AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc (GSK), Eli Lilly and Company, Amgen, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Astellas Pharma, AptarGroup, Chiesi Farmaceutici S.p.A., Dr. Reddy’s Laboratories, Cipla Inc., Lupin Limited, Zydus Cadila, Glenmark Pharmaceuticals, Vectura Group, and Aurobindo Pharma.
North America was the largest region in the asthma and COPD drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in asthma and COPD drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the asthma and COPD drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The asthma and COPD drugs market consists of sales of bronchodilators, inhaled corticosteroids, combination inhalers, leukotriene modifiers, biologics, theophylline, and systemic corticosteroids. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The asthma and COPD drugs market size is expected to see strong growth in the next few years. It will grow to $50.99 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. This anticipated growth is driven by the rising preference for personalized treatment approaches, the growing use of biologics and next-generation therapies, a surge in environmental allergy cases, expansion in clinical trials and regulatory approvals, and the increasing prevalence of chronic non-communicable diseases. Notable trends projected during the forecast period include the emergence of smart inhaler technologies, development of dual-action bronchodilators, integration of drug data with electronic health records (EHRs), advancements in biopharmaceutical innovations, and the application of machine learning in the drug development process.
Major players in the asthma and COPD drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd. (Roche), Merck & Co. Inc., Sanofi, AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc (GSK), Eli Lilly and Company, Amgen, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Astellas Pharma, AptarGroup, Chiesi Farmaceutici S.p.A., Dr. Reddy’s Laboratories, Cipla Inc., Lupin Limited, Zydus Cadila, Glenmark Pharmaceuticals, Vectura Group, and Aurobindo Pharma.
North America was the largest region in the asthma and COPD drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in asthma and COPD drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the asthma and COPD drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The asthma and COPD drugs market consists of sales of bronchodilators, inhaled corticosteroids, combination inhalers, leukotriene modifiers, biologics, theophylline, and systemic corticosteroids. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Characteristics3. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Trends And Strategies4. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market32. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Competitive Benchmarking And Dashboard33. Key Mergers And Acquisitions In The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market34. Recent Developments In The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market
5. Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Growth Analysis And Strategic Analysis Framework
6. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Segmentation
7. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Regional And Country Analysis
8. Asia-Pacific Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market
9. China Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market
10. India Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market
11. Japan Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market
12. Australia Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market
13. Indonesia Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market
14. South Korea Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market
15. Western Europe Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market
16. UK Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market
17. Germany Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market
18. France Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market
19. Italy Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market
20. Spain Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market
21. Eastern Europe Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market
22. Russia Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market
23. North America Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market
24. USA Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market
25. Canada Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market
26. South America Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market
27. Brazil Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market
28. Middle East Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market
29. Africa Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market
30. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Competitive Landscape And Company Profiles
31. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Other Major And Innovative Companies
35. Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on asthma and chronic obstructive pulmonary disease (copd) drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for asthma and chronic obstructive pulmonary disease (copd) drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The asthma and chronic obstructive pulmonary disease (copd) drugs market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Drug Class: Bronchodilators; Corticosteroids; Combination Drugs; Leukotriene Modifiers2) By Route Of Administration: Inhalation; Oral; Injection; Nasal; Other Route Of Administrations
3) By Patient Group: Adult; Pediatric; Geriatric
4) By Application: Asthma; Chronic Obstructive Pulmonary Disease; Allergic Rhinitis; Pulmonary Hypertension
5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Drug Stores
Subsegments
1) By Bronchodilators: Short-Acting Beta-2 Agonists (SABA); Long-Acting Beta-2 Agonists (LABA); Anticholinergics; Long-Acting Muscarinic Antagonists; Methylxanthines2) By Corticosteroids: Inhaled Corticosteroids (ICS); Oral Corticosteroids; Intravenous Corticosteroids
3) By Combination Drugs: Long-Acting Beta-Agonist + Inhaled Corticosteroid; Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist; Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist + Inhaled Corticosteroid
4) By Leukotriene Modifiers: Leukotriene Receptor Antagonists; Leukotriene Synthesis Inhibitors
Key Companies Profiled: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd. (Roche); Merck & Co. Inc.; Sanofi
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Pfizer Inc.
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd. (Roche)
- Merck & Co. Inc.
- Sanofi
- AstraZeneca Plc
- Novartis AG
- GlaxoSmithKline Plc (GSK)
- Eli Lilly and Company
- Amgen
- Teva Pharmaceutical Industries Ltd.
- Boehringer Ingelheim
- Astellas Pharma
- AptarGroup
- Chiesi Farmaceutici S.p.A.
- Dr. Reddy’s Laboratories
- Cipla Inc.
- Lupin Limited
- Zydus Cadila
- Glenmark Pharmaceuticals
- Vectura Group
- Aurobindo Pharma